Abeona holds constructive Pre-IND meeting with FDA for ABO-701; IND target 2027

ABEONA THERAPEUTICS INC.

Pre-IND meeting with FDA held June 3, 2026 for ABO-701, a T-cell therapy targeting PSMA for prostate cancer.
Company characterizes meeting as constructive; official FDA minutes not yet received.
IND submission for ABO-701 remains targeted for 2027, consistent with prior guidance.
No assurance that FDA will accept IND or that additional studies won't be required.
Development plans subject to revision based on FDA feedback, preclinical results, and manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.